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Human memory but not naïve ␥␦ T cells from TST-positive individuals respond to M tuberculosis antigen
We thank Casetti et al for their interest in our recent work, "CD4 ϩ CD25 ϩ Treg cells inhibit human memory ␥␦ T cells to produce IFN-␥ in response to M tuberculosis antigen ESAT-6." 1 In our article, we showed that stimulation of peripheral blood mononuclear cells (PBMCs) from tuberculin skin test (TST)-positive individuals with ESAT-6 resulted in not only the production of cytokines but also the activation and division of memory ␥␦ T cells. These responding ␥␦ T cells displayed the phenotype of memory but not naive ␥␦ T cells. Most interestingly, CD4 ϩ CD25 ϩ Treg cells could inhibit IFN-␥ production by ␥␦ T cells.
Casetti et al observed that CD4 ϩ but not ␥␦ T cells from 4 patients with active tuberculosis (TB) disease and 4 subjects with latent TB infection (LTBI) responded to ESAT-6 to express IFN-␥. In accordance with their and others' observations, 2 in our unpublished data from a few active TB patients, we also found that CD4 ϩ T cells, in addition to ␥␦ T cells, produced IFN-␥ in response to ESAT-6. Of note, the cells from different individuals with TB infection had distinct quality of response. The discrepancies between their and our results on the response of ␥␦ T cells to ESAT-6 might be influenced by many factors. The concern might be that the source of ESAT-6 we purchased from suppliers was different from that Casetti et al used. The various preparations of recombinant antigens, including cloning, sequences, expression, and purification process from different companies, might have different biologic activities. Moreover, differences in the classical and nonclassical major histocompatibility class (MHC) molecules, the affinity to antigenic epitopes, and the distinct biologic features between eastern and western peoples might lead to distinct reactivity to the same antigen. Clearly, it has been reported that ␥␦ T cells from bovines could react to ESAT-6 by IFN-␥ production and proliferation. 3 In addition, several antigenic epitopes/proteins recognized by human ␥␦ T cells have been identified via CDR3␦ peptide-based immunobiochemical strategy. 4 These peptides not only bind to ␥␦ T cells but also activate ␥␦ T cells. Moreover, in human chronic human herpesvirus 8 (HHV-8) infection, purified viral proteins resulted in ␥␦ V␦1 T cell activation. 5 Taken together, we agree with Casetti et al that human ␥␦ T cells recognize nonpeptidic phosphoantigens, metabolites of the isoprenoid pathway. 6, 7 However, the mechanism by which human ␥␦ T cells recognized protein antigens remains unclear currently and needs further investigation. To the editor:
Is exclusive Skp2 targeting always beneficial in cancer therapy?
We read with great interest the work published in Blood by Chen et al concerning the therapeutic restoration of p27 KIP1 protein levels in cancer after applying the specific Skp2 inhibitor CpdA. 1 Skp2 is an E3-ubiquitin ligase that mediates degradation of several cell-cycle regulators. 2 Among its targets are negative cell-cycle regulators, including the kinase inhibitor protein (KIP) family member p27 KIP1 , and positive ones, such as cyclin E. 2 In addition, p27 KIP1 also inhibits cyclin E. 2 Thus, Skp2, p27 KIP1 , and cyclin E form a tight network controlling S-phase entry. 2 In various tumors Skp2 is frequently overexpressed and represents a major cause of p27 KIP1 protein down-regulation. 2 However, p27 KIP1 gene alterations and transcriptional silencing, due to microRNA-dependent repression, promoter methylation, and transcriptional suppressors, is not a rare event, as the authors mention, 1 but a significant source of p27 KIP1 inactivation in several malignancies (Table S1 , available on the Blood website; see the Supplemental Materials link at the top of the article). Consequently, we cannot exclude the possibility that Skp2 overexpression coexists with transcriptionally silenced and/or mutant p27 KIP1 . We have observed such a condition with the other KIP member and Skp2 target, p57 KIP2 . 3 Based on the above, Skp2 inhibition, in cases with transcriptionally silenced and/or mutant p27 KIP1 , could result in increased expression of cyclin E with potential deleterious effects. Cyclin E provokes genomic instability, when overexpressed, by producing either DNA damage and/or centrosome amplification. 4, 5 Upregulation of cyclin E is frequently observed in cancer, and is associated in various malignancies with poor survival. 6 To test this hypothesis we mimicked the above scenario by silencing Skp2 alone or in combination with p27 KIP1 in A549 cancer cells, which express high Skp2 levels. 3 The experiment showed that sole Skp2 silencing resulted in elevation of p27 KIP1 , reduction of cyclin E expression ( Figure 1A,B) , and a decrease in growth, 3 while Skp2/p27 KIP1 double knockout, recapitulating the proposed scenario, led to increased levels of cyclin E ( Figure  1A ,B), centrosome amplification ( Figure 1B) , abnormal mitoses, and pronounced nuclear atypia characterized by micronuclei, lobulated nuclei, and nucleoplasmic bridges, features that are indicative of chromosomal instability ( Figure 1C) . 7 In addition, marked p53 Ser-15 phosphorylation ( Figure 1A) , indicating a prominent DNA damage response, provides a mechanistic explanation for the observed genomic instability. 8, 9 Furthermore, the elevated levels of cyclin E comprised not only KIP1 , cyclin E and low-molecular-weight isoforms, Ser15 phosphorylated p53 levels in A549 mock, siSkp2-, and siSkp2/p27 KIP1 -treated cells. (B) Impact of deregulated cyclin E expression on centrosome status after Skp2 and Skp2/p27 KIP1 silencing in A549 cells. Immunofluorescence analysis (Texas Red ϭ cyclin E, Oregon Green ϭ ␥-tubulin) and counterstaining with DAPI. A549 mock cells demonstrate moderate nuclear staining of cyclin E accompanied by centrosome amplification (top panel, magnification ϫ600). A549 siSkp2 cells display normal centrosomal profile (arrow) and suppression of cyclin E expression (middle panel). A549 siSkp2/p27 KIP1 cells showed increased, cyclin E levels (accumulation of both nuclear and cytoplasmic isoforms) and centrosome aggregates (arrows; bottom panel). (C) Abnormal mitoses, micronuclei, nuclear lobulation, and nucleoplasmic bridges in A549 siSkp2/p27 KIP1 cells. Cells were counterstained with DAPI. Histograms depict percentages of abnormal mitoses (P ϭ .001, ANOVA) and micronuclei (P Ͻ .001, ANOVA) in A549 mock and A549 siSkp2/p27 KIP1 -treated cells. Images in panels B and C were viewed through a Zeiss Axiolab microscope with 63 times 0.80, Zeiss Achroplan lens (both Carl Zeiss, AntiSel). Cell spreads were mounted in Fluoromount G. Texas Red was used to detect cyclin E, Oregon Green to detect ␥-tubulin, and DAPI as a counterstain (Invitrogen, AntiSel). Images were photographed with a SenSys camera (Photometrics, Tucson, AZ) and processed with SmartCapture VP software version 1.4 (Digital Scientific, Cambridge, United Kingdom).
the full-length but also the low-molecular-weight isoforms. 5, 6 These isoforms are present in both cytoplasm and nucleus, and have increased affinity for cdk2. 5, 6 They have been associated with genomic instability, resistance to CIP/KIP inhibition, and poor outcome of patients with various malignancies. 6 Similarly, is exclusive Skp2 targeting efficient in patients with p27 KIP1 haploinsufficiency? 10 In such cases, SKP2 blocking is effective when the levels of the remaining p27 KIP1 allele are up-regulated above a threshold, able to exert its negative effect on cell-cycle progression. Below this threshold the CIP/KIP molecules will be sequestered by the cyclin D/cdk complexes, further promoting cyclin E/cdk2 activity. 11 In conclusion, although the findings of Chen et al are significant and important, our results present an additional point of view, which stresses the impact of defining the transcriptional and/or mutational status of p27 KIP1 before applying a therapeutic approach based exclusively on Skp2 inhibition. 
